AstraZeneca announced the official launch of the innovative drug Innovan® in China. In April of this year, based on the positive results of the global phase III HIMALAYA study and the Chinese cohort, trimelizumab combined with Infinefan® was approved in China for first-line treatment of adult patients with advanced or unresectable hepatocellular carcinoma.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.